Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.

Details

Serval ID
serval:BIB_4BF870FE046B
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.
Journal
Journal of the European Academy of Dermatology and Venereology
Author(s)
Noël B.
ISSN
0926-9959 (Print)
ISSN-L
0926-9959
Publication state
Published
Issued date
01/2007
Volume
21
Number
1
Pages
17-24
Language
english
Notes
Publication types: Journal Article ; Review
Abstract
BACKGROUND: Statins have been increasingly associated with drug-induced autoimmune reactions, including lupus erythematosus.
OBJECTIVE: To identify and determine the clinical and biological characteristics of statin-induced autoimmune reactions.
MATERIAL AND METHODS: The MEDLINE database (1966 to September 2005) was used to identify all reported cases of statin-induced autoimmune diseases. The keywords used were statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, adverse effects, autoimmune disease, lupus erythematosus, dermatomyositis and polymyositis.
RESULTS: Twenty-eight cases of statin-induced autoimmune diseases have been published so far. Systemic lupus erythematosus was reported in 10 cases, subacute cutaneous lupus erythematosus in three cases, dermatomyositis and polymyositis in 14 cases and lichen planus pemphigoides in one case. Autoimmune hepatitis was observed in two patients with systemic lupus erythematosus. The mean time of exposure before disease onset was 12.8+/-18 months; range 1 month-6 years. Systemic immunosuppressive therapy was required in the majority of cases. In many patients, antinuclear antibodies were still positive many months after clinical recovery. A lethal outcome has been recorded in two patients despite aggressive immunosuppressive therapy.
CONCLUSION: Long-term exposure to statins may be associated with drug-induced lupus erythematosus and other autoimmune disorders. Fatal cases have been reported despite early drug discontinuation and aggressive systemic immunosuppressive therapy.
Keywords
Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects, Lupus Erythematosus, Systemic/chemically induced, Lupus Erythematosus, Systemic/pathology, Risk Factors
Pubmed
Web of science
Create date
29/01/2008 18:23
Last modification date
20/08/2019 15:00
Usage data